Sepracor Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Sepracor in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Report Highlights

[Studien Infos ausblenden]

CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
Sepracor: PharmaVitae forecasts at a glance 7
Strategic insight 8
Stereoisomer purification drives unique business model 8
Near-term growth potential squeezed by market pressures 10
Xopenex sales hit by new reimbursement rate 10
Ambien generics arrest further Lunesta uptake 11
Operating profit margin flat through 2008 11
SWOT analysis 12
Strengths 12
Weaknesses 14
Opportunities 15
Threats 16
CHAPTER 3 QUARTERLY NEWS UPDATE 20
Product developments 20
Deals and alliances 21
Product deals 21
Technology deals 21
M&A activity 22
Company announcements 22
Future product milestones 23
CHAPTER 4 COMPANY INTRODUCTION 24
Key findings 24
Background 25
Key corporate developments 25
M&A history 27
IBF Biotechnics acquired 27
Spin off of BioSepra and HemaSure 27
Merger of SepraChem with Sterling Organics 27
Divestment of Versicor Pharmaceuticals 27
Oryx Pharmaceuticals 28
CHAPTER 5 COMPANY SALES 29
Key findings 29
Prescription pharmaceutical sales and growth rate analysis, 2001-13 30
Historical analysis 31
Forecast analysis 31
Product analysis 33
Product analysis, 2001-07 34
Growth drivers 35
Product analysis, 2007-13 36
Growth drivers 37
Growth resistors 39
Therapy area analysis 40
Therapy area analysis, 2001-07 41
Therapy area analysis, 2007-13 42
Therapy area focus, 2001-13 43
Geographic analysis 44
Geographic analysis, 2001-07 45
Geographic analysis, 2007-13 46
Launch/core/expiry analysis 48
Explanation of launch/core/expiry analysis 48
Launch analysis, 2007-13 49
Core analysis, 2007-13 50
Expiry analysis, 2007-13 51
Launch/core/expiry configuration, 2007-13 52
Molecule type analysis 53
Molecule type analysis, 2001-07 54
Molecule type analysis, 2007-13 54
Externalization analysis 55
Externalization analysis, 2001-07 56
Externalization analysis, 2007-13 56
CHAPTER 6 COMPANY FINANCIALS 58
Key findings 58
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 59
Financial statements, 2001-07 60
Profit and loss account, 2001-07 60
Balance sheet, 2001-07 61
Operating costs and profit analysis 62
Operating costs and profit analysis, 2001-07 63
Operating cost ratio and profit margin analysis, 2001-07 64
Operating cost ratio and profit margin analysis, 2007-13 65
Operating costs and profit analysis, 2007-13 67
Return on capital employed analysis 69
Capital employed analysis, 2001-07 70
Return on capital employed analysis, 2001-07 72
Market capitalization analysis 74
Market capitalization analysis, 2001-07 74
Total shareholder returns analysis, 2001-07 76
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 77
Key findings 77
Overview 78
Respiratory 79
Brovana 79
Overview 80
Sales forecast 81
Xopenex franchise (Xopenex Inhalation Solution/Xopenex HFA) 83
Overview 84
Sales forecast 86
Ciclesonide franchise (Alvesco/Omnaris) 89
Overview 90
Sales forecast 92
Central nervous system 96
Lunesta 96
Overview 97
Sales forecast 98
Ambien generics arrest further Lunesta prescriptions 99
CHAPTER 8 APPENDIX 102
R&D pipeline 102
References 103
Abbreviations 104
Exchange rates 105
[Inhaltsverzeichnis ausblenden]

Table 1: Sepracor - PharmaVitae forecasts at a glance 7
Table 2: Sepracor key product developments, Q1-Q3 2008 20
Table 3: Sepracor product deals and alliances, Q1 2008 21
Table 4: Sepracor technology deals and alliances, Q1 2008 21
Table 5: Sepracor M&A activity, Q1-Q3 2008 22
Table 6: Sepracor company announcements, Q1 2008 22
Table 7: Sepracor future product milestones, 2008-10 23
Table 8: Sepracor product portfolio overview ($m), 2001-07 34
Table 9: Sepracor product portfolio overview ($m), 2007-13 36
Table 10: Sepracor product portfolio overview ($m), 2001-07 41
Table 11: Sepracor product portfolio overview ($m), 2007-13 42
Table 12: Sepracor portfolio overview by geographic region ($m), 2001-07 45
Table 13: Sepracor portfolio overview by geographic region ($m), 2007-13 46
Table 14: Sepracor launch portfolio overview ($m), 2007-13 49
Table 15: Sepracor core portfolio overview ($m), 2007-13 50
Table 16: Sepracor expiry portfolio overview ($m), 2007-13 51
Table 17: Sepracor portfolio overview by molecule type ($m), 2001-07 54
Table 18: Sepracor product portfolio overview by molecule type ($m), 2007-13 54
Table 19: Sepracor product portfolio overview by source ($m), 2001-07 56
Table 20: Sepracor product portfolio overview by source ($m), 2007-13 56
Table 21: Total Sepracor sales by business unit ($m), 2001-07 59
Table 22: Sepracor profit and loss account ($m), 2001-07 60
Table 23: Sepracor balance sheet ($m), 2001-07 61
Table 24: Sepracor operating revenue/cost analysis ($m), 2001-07 63
Table 25: Sepracor operating cost ratio analysis (% of total revenues), 2001-07 64
Table 26: Sepracor operating cost ratio analysis (% of total revenues), 2007-13 65
Table 27: Sepracor operating revenue/cost analysis ($m), 2007-13 67
Table 28: Sepracor capital employed ($m), 2001-07 70
Table 29: Sepracor EBIT return on capital employed ($m), 2001-07 72
Table 30: Sepracor EBIT pre-tax return/capital employed driver analysis (%), 2001-07 73
Table 31: Sepracor market capitalization ($ billion), 2001-07 74
Table 32: Sepracor total shareholder returns (annual %), 2001-07 76
Table 33: Key products overview 78
Table 34: Brovana: overview 80
Table 35: Brovana: sales forecast ($m), 2007-13 81
Table 36: Xopenex Inhalation Solution: overview 84
Table 37: Xopenex HFA: overview 85
Table 38: Xopenex Inhalation Solution: sales forecast ($m), 2007-13 86
Table 39: Xopenex HFA: sales forecast ($m), 2007-13 86
Table 40: Alvesco: overview 90
Table 41: Omnaris: overview 91
Table 42: Alvesco: sales forecast ($m), 2007-13 92
Table 43: Omnaris: sales forecast ($m), 2007-13 92
Table 44: Lunesta: overview 97
Table 45: Lunesta: sales forecast ($m), 2007-13 98
Table 46: Sepracor's R&D pipeline (Phase I-registration) 102
Table 47: Exchange rates, 2007 105
Figure 1: Sepracor prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Sepracor's financial performance ($m), 2001-13 6
Figure 3: Sepracor's marketed stereoisomer preparations 8
Figure 4: Sepracor SWOT analysis 12
Figure 5: Sepracor prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 30
Figure 6: Sepracor key sales growth driver & resistors ($m), 2001-07 34
Figure 7: Sepracor key sales growth drivers & resistors ($m), 2007-13 37
Figure 8: Sepracor prescription pharmaceutical sales by therapy area ($m), 2001-13 40
Figure 9: Sepracor prescription pharma sales by therapy area (% of total), 2001-13 43
Figure 10: Sepracor prescription pharmaceutical sales by geographic region ($m), 2001-13 44
Figure 11: Sepracor drivers and resistors by geographic region ($m), 2007-13 47
Figure 12: Sepracor launch/core/expiry configuration ($m), 2007-13 52
Figure 13: Sepracor prescription pharmaceutical sales by molecule type ($m), 2001-13 53
Figure 14: Sepracor prescription pharmaceutical sales by source ($m), 2001-13 55
Figure 15: Sepracor growth drivers and resistors by source ($m), 2007-13 57
Figure 16: Sepracor operating revenue/cost analysis ($m), 2001-13 62
Figure 17: Sepracor operating cost ratio analysis (% of total revenues), 2001-13 66
Figure 18: Sepracor's return on capital employed, EBIT margin and capital turnover, 2001-07 69
Figure 19: Return on capital employed formula 73
Figure 20: Sepracor market capitalization ($ billion), 2001-07 75
Figure 21: Sepracor total shareholder returns vs. S&P 500 ($m), 2001-07 76
Figure 22: Share of US nonbenzodiazepine prescriptions (%), Q107-Q208 100
[Tabellenverzeichnis ausblenden]